$287 Million is the total value of Opaleye Management Inc.'s 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | BIOHAVEN LTD | $7,495,200 | – | 540,000 | +100.0% | 2.61% | – | |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $6,240,832 | – | 923,200 | +100.0% | 2.17% | – |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $4,684,350 | – | 417,500 | +100.0% | 1.63% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $4,281,994 | – | 1,206,841 | +100.0% | 1.49% | – |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $3,373,450 | – | 167,500 | +100.0% | 1.17% | – |
| New | MARINUS PHARMACEUTICALS INC | $3,288,276 | – | 826,200 | +100.0% | 1.14% | – | |
| New | AADI BIOSCIENCE INC | $3,233,750 | – | 252,046 | +100.0% | 1.12% | – | |
| FENC | New | FENNEC PHARMACEUTICALS INC | $2,613,120 | – | 272,200 | +100.0% | 0.91% | – |
| BCAB | New | BIOATLA INC | $2,159,850 | – | 261,800 | +100.0% | 0.75% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $982,872 | – | 87,600 | +100.0% | 0.34% | – |
| TRVI | New | TREVI THERAPEUTICS INC | $936,050 | – | 485,000 | +100.0% | 0.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.